EGFR and cancer: PEG engagerEGFR significantly enhanced the anti-proliferation activity of Doxisome (Fig. 5 and Supplementary Fig. 4) and PEG-liposomal vinorelbine (Supplementary Fig. 5) against EGFR-positive cancer cells as compared with drug-loaded nanocarrier alone, drug-loaded nanocarrier plus PEG engagerCD19 or empty liposomes with PEG engagerEGFR.